2024年5月14日 · BTK inhibitors (BTKis) are established standards of care in multiple B-cell malignancies including chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom macroglobulinemia. The first-generation BTKi ibrutinib demonstrated superiority over standard chemoimmunotherapy regimens in multiple randomized trials but is limited by ...

In this review, we discuss the role of BTK inhibitors in treatment of CLL/SLL, review the data that led to approval of BTK inhibitors in CLL/SLL, outline the toxicity profile of each approved BTK inhibitor and management, and give practical guidance on how to select the most appropriate agent for treatment.

Here, we review the role of Bruton tyrosine kinase (BTK) inhibitors in treating patients with treatment-naïve and relapsed or refractory CLL. We review recent approvals of BTK inhibitors as well as reported and ongoing clinical trial data.

BTK inhibitors (BTKis) have revolutionized the treatment of chronic lymphocytic leukemia (CLL) and other B cell malignancies. Besides their well-characterized role in inhibiting BCR signaling, BTKis also exert significant immunological influences outside the tumor cell that extend their therapeutic potential and impact on the immune system in ...

欧洲肿瘤内科学会（ESMO）的CLL一线治疗指南包括BTK抑制剂（BTKi，即 伊布替尼 和 阿卡替尼 ）、BCL2i维奈托克联用或不联用奥妥珠单抗（obinutuzumab），以及PI3Ki艾代拉里斯（idelalisib）联用利妥昔单抗，但后者由于感染性毒性而很少使用。

布鲁顿酪氨酸激酶（BTK）是BCR信号通路关键组成部分，在CLL中呈高表达状态，BTK抑制剂（BTKi）的成功研发，为治疗CLL带来了突破性进展。 伊布替尼（Ibrutinib）为首个获批用于治疗CLL的BTKi，通过与BTK活性部位481位置的半胱氨酸残基形成共价键抑制BTK活性，阻断BCR多个下游信号通路达到治疗效果 [2]。 多个临床试验的长期随访结果表明伊布替尼可以显著延长复发/难治CLL（R/R CLL）患者和初治CLL（TN CLL）患者的无进展生存（PFS）期与总生 …

2024年12月1日 · Bruton Tyrosine Kinase inhibitors (BTKi) disrupt the BCR signaling pathway by inactivation of BTK, leading to inhibition of proliferation and survival of CLL cells. There are two classes of BTK inhibitors, covalent and non-covalent. İbrutinif is the first approved covalent BTKi (cBTKi) of its class.

2023年5月2日 · 自2017年以来，布鲁顿酪氨酸激酶（BTK）抑制剂在我国陆续上市，其在临床上的广泛应用，使得我国慢性淋巴细胞白血病（CLL）/小淋巴细胞淋巴瘤（SLL）的治疗发生了翻天覆地的变化。 随着不同BTK抑制剂在国际指南推荐地位的变化，2022年《中国CLL/SLL的诊断与治疗指南》（以下简称“指南”） [1]再次更新，并确立BTK抑制剂的治疗地位！ 让我们聚焦指南，展望CLL/SLL未来治疗之道。 大放异彩，BTK抑制剂在CLL/SLL治疗领域获得巨大成功. BTK是一 …

2023年8月16日 · BTK inhibition in CLL cells does not result in massive immediate killing of CLL cells like venetoclax or chemotherapy. Still, it does deprive the CLL cell of key signals for proliferation and survival, leading to eventual cell death. The first approved BTK inhibitor, ibrutinib, revolutionized the treatment of CLL and SLL and significantly ...

2024年11月7日 · 慢性淋巴细胞白血病中探索的两药方案包括BTK抑制剂联合CD20单抗、BTK抑制剂联合BCL2抑制剂（主要是固定周期治疗和MRD驱动治疗），三药方案包括BTK抑制剂联合CD20单抗和BCL2抑制剂（包括固定周期治疗）。 套细胞淋巴瘤中探索的方案包括BTK抑制剂联合CD20单抗（年轻和老年患者的研究均获得成功）、BTK抑制剂纳入适合移植患者的一线免疫化疗（例如联合BR，以及TRIANGLE研究中联合R-CHOP/R-DHAP±ASCT）、BTK抑制剂联 …